Aoti, Inc.: Grant of awards under Long Term Incentive Plan

Aoti

23/04/2026 07:00

RNS Number : 5537B

AOTI, Inc.

23 April 2026

 

23 April 2026

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Grant of performance share awards to CEO, CFO and COO under Long Term Incentive Plan

 

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces that on 22 April 2026, the Company granted awards over ordinary shares in the form of options (Performance Awards) under the AOTI Long Term Incentive Plan (LTIP) to Mike Griffiths, CEO, Jayesh Pankhania, CFO, and Anthony Moffatt, COO, who are Persons Discharging Managerial Responsibilities (PDMR), as detailed below:

 

PDMR
Role
Number of Performance Awards
Exercise Price (GBP)
Mike Griffiths
CEO
678,471
0.37
Jayesh Pankhania
CFO
377,099
0.37
Anthony Moffatt
COO
270,672
0.37

 

The Performance Awards will vest three years from the grant date conditional on meeting three-year performance conditions as described below.

 

50% of an award is subject to an Adjusted EBITDA1 performance condition measured over a three-year period ending 31 December 2028.

 

50% of an award is subject to an Adjusted EBITDA margin2 performance condition measured over a three-year period ending 31 December 2028.

 

1 Adjusted EBITDA is an unaudited non-GAAP measure: Earnings before interest, taxation, depreciation, amortisation and non-underlying items.

2 Adjusted EBITDA margin is Adjusted EBITDA divided by Revenue

 

END

 

AOTI, INC.
Dr. Mike Griffiths, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
+44 (0)20 3727 1000
ir@aotinc.net
Peel Hunt LLP (Nominated Adviser and Joint Broker)
Dr. Christopher Golden, James Steel
+44 (0)20 7418 8900
Panmure Liberum Limited (Joint Broker)
Emma Earl, Will Goode, Mark Rogers
Rupert Dearden
+44 (0)20 3100 2000
FTI Consulting (Financial PR & IR)
Ben Atwell, Simon Conway,
Natalie Garland-Collins
+44 (0)20 3727 1000
AOTI@fitconsulting.com

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net

 

 

1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
1. Mike Griffiths
2. Jayesh Pankhania
3. Anthony Moffatt
2.
Reason for notification
a)
Position / status
1. CEO
2. CFO
3. COO
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
AOTI, INC.
b)
LEI
213800ZGCNDSTWIRK687
4.
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a)
Description of the financial instrument
Ordinary Shares
b)
Identification code
US03690C1027
c)
Nature of transactions
Award under the AOTI LTIP
d)
Price(s) and volume(s)
Exercise Price:
1. GBP0.37
2. GBP0.37
3. GBP0.37
Volume:
1. 678,471
2. 377,099
3. 270,672
e)
Aggregated Information
- Aggregated volume
- Price
As for d) above
f)
Date of the transactions
22 April 2026
g)
Place of the transactions
Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBLGDSIDDDGLD